Tamoxifen increases plasma estrogen-binding equivalents and has an estradiol agonistic effect on histologically normal premenopausal and postmenopausal endometrium

This publication has 15 references indexed in Scilit:

• Endocrine Pharmacology of Antiestrogens as Antitumor Agents*
  Endocrine Reviews, 1990
• Tamoxifen-associated endometrial carcinoma in postmenopausal breast cancer patients
  Gynecologic Oncology, 1990
• Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization.
  Proceedings of the National Academy of Sciences, 1990
• Mechanism of the Estrogen Receptor Interaction with 4-Hydroxytamoxifen
  Molecular Endocrinology, 1988
• Extensivein SituActivation of Nuclear Estrogen Receptors after Exposure of Murine Uteri to [³H]Estradiol or [³H]4-Hydroxytamoxifen*
  Endocrinology, 1987
• Characterization and assay of the nuclear and cytosolic progesterone (P) receptors in Premarin -primed human endometrium and myometrium after single-dose P administration
  Fertility and Sterility, 1986
• The pharmacology and clinical uses of tamoxifen
  Pharmacology & Therapeutics, 1984
• Estrogen-Like Action of Tamoxifen on Vaginal Epithelium in Breast Cancer Patients
  Oncology, 1981
• High-affinity anti-oestrogen binding site distinct from the oestrogen receptor
  Nature, 1980
• Cytoplasmic and Nuclear Estradiol and Progesterone Receptors in Human Endometrium*
  Journal of Clinical Endocrinology & Metabolism, 1978